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Sir,
A recent study from China identiﬁed transferable polymyxin resist-
ance in Gram-negative bacilli from human and animal isolates.1
Although polymyxins, including colistin and polymyxin B, were
among the very few antibiotics for which no transferable re-
sistance had been identiﬁed, we are now facing a novel threat
with the identiﬁcation of a plasmid-encoded resistance mechan-
ism. Colistin is an old drug that was ﬁrst introduced in 1959
but remained on the shelf for many years due to renal and neuro-
toxicity.2 However, we are experiencing a renewed interest in
this drug due to the rapid emergence of MDR Gram-negative
organisms.
The plasmid-borne mcr-1 gene encodes a phosphoethanola-
mine transferase that mediates addition of phosphoethanola-
mine to the lipid A moiety of the lipopolysaccharide, consequently
conferring resistance to polymyxins.1 This gene has thus far mainly
been found in Escherichia coli, and toa lesser extent in Klebsiella spp.
and Salmonella spp.
Very shortly after the original report, other studies reported
identiﬁcation of the mcr-1 gene in human E. coli isolates in
many different countries, including in Algeria, Denmark, France,
Germany, Laos, the Netherlands, Malaysia, Nigeria, Switzerland
and Thailand.3–5 It was also identiﬁed from imported food pro-
ducts in Denmark (meat) and Switzerland (vegetables).6,7 In add-
ition, plasmid-encoded carbapenem and colistin resistance may
be co-associated in E. coli.3,5,8 In addition, positive Salmonella
enterica isolates of different serotypes were identiﬁed from food
samples in Portugal in 2011, and France in 2012 and 2013.9,10
Finally, an epidemiological survey conducted in France on a collec-
tion of ESBL-producing E. coli isolates (n¼517) recovered from the
faeces of diarrheic veal calves on farms from 2005 to 2014
showed a very high rate of MCR-1-positive isolates (20.5%).11
Taken together, these ﬁndings indicate that: (i) the spread of
mcr-1 is not recent, as it has alreadyoccurredworldwide, probably
due to its location on conjugative plasmids; and (ii) E. coli is so far
the main reservoir of this resistance trait among human, animal
and environmental isolates. This is a source of concern since
E. coli isolates are easily exchanged from the environment to
humans in which they may remain as a commensal in the gut
ﬂora; in addition, E. coli is the number one pathogen for humans.
MCR-1 is one of the fewand clear examples of the animal origin
of a resistance trait that may later hit the entire human health
system, along with the examples of some MRSA clones (such as
CC398), the serotype O104:H4 CTX-M-15 ESBL-producing enter-
oaggregative E. coli and ESBL-producing Salmonella spp. strains.
The animal origin of MCR-1 is sustained by: (i) the number of
reports of animal isolates expressing mcr-1, which is already high;
and (ii) heavy usage of colistin in veterinary medicine. By standard-
izing the sales of antimicrobials in relation to the total weight of ani-
mals ‘at risk’ undergoing treatment across Europe in 2011, it was
estimated that polymyxins are the ﬁfth most sold group of antimi-
crobials (7%).12 In Europe, colistin and polymyxin B are used for
treating infections caused by Enterobacteriaceae in rabbits, broilers,
veal, beef cattle, dairy cattle and (primarily) pigs. In addition, in
other parts of the world, polymyxins are used as growth promoters,
a usage that has been banned in Europe since 2006. The animal ori-
gin of MCR-1 is also sustained by the genetics associated with the
mcr-1 gene.When investigating themcr-1-positive E. coli KRI recov-
ered from the urine of a community patient in Switzerland,3 an
insertion sequence (ISApl1) was identiﬁed upstream of the mcr-1
gene that was 100% identical to one identiﬁed in Pasteurellamulto-
cida, which is a common animal pathogen, in particular for pigs. In
addition, this same E. coli co-expressed the broad-spectrum
b-lactamase gene blaCMY-2, and the ﬂorfenicol resistance gene
ﬂoR, both genes that are widely disseminated in animal isolates,
with ﬂorfenicol being used in veterinary medicine only.
It seems very likely that the occurrence of polymyxin resistance
in animal isolates has been underestimated and unrecognized for
years, since the determination of polymyxin susceptibility is difﬁ-
cult. Disc diffusion and Etest are not reliable techniques, and broth
microdilution is the gold standard technique but it is cumbersome
and not used on a regular basis, in particular in veterinary medi-
cine. Therefore, there is an urgent need for rapid diagnostic tests
for polymyxin resistance in Enterobacteriaceae.
The impact of the use of polymyxins in agriculture was not ser-
iously taken into account as long as there was no critical need for
colistin in human medicine. However, times have changed and a
co-ordinated re-evaluation of polymyxin usage in agriculture is
urgently needed to prevent selection in veterinary medicine of
polymyxin-resistant isolates that might subsequently be trans-
ferred to humans. Similarly, using polymyxins in selective digest-
ive decontamination to prevent the spread of MDR bacteria in
hospitals should be discouraged. Nevertheless, a decision to ban
polymyxins in agriculturewould be far from simple andmight be a
matter of balancing risk against beneﬁts.
In a recent review debating the use of colistin-containing pro-
ducts within the European Union and European Economic Area,
Catry et al.12 concluded by stating ‘Should colistin resistance
determinants be found on mobile genetic elements in bacteria
of concern from human or animal origin, or should a clonal expan-
sion of pathogenic polymyxin-resistant bacteria take place, fur-
ther risk proﬁling would be required’. Here we are, unfortunately!
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